Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary
Otherwith gamma-camera and D.SPECT camera
NCT Number: NCT02861235
Myocardial perfusion tomoscintigraphy is a routine medicine procedure to check for the presence and severity of abnormalities of myocardial perfusion, as well as the extension of infarction residua. However, actual imagery devices (gamma cameras) have low resolution and detection sensitivity. A new semiconductor camera has 8 to 10 time higher detection sensitivity and could allow proportionally diminishing injected activities or recording times. Only one pilot study has been recently published on this type of camera, the D.SPECT camera.
This study will compare images recorded during 15 to 20 minutes by conventional cameras and 2 to 4 minutes by D.SPECT camera in patients doing tomoscintigraphy under usual conditions. The purpose is to demonstrate the equivalence of images recorded by two camera types for diagnostic information and the secondary purpose is to demonstrate the superiority of the D.SPECT camera in terms of image quality.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Service de Médecine Nucléaire, Hôpital de Bichat, Assistance Publique des Hôpitaux de Paris, Paris, France
This study will be conducted in Nuclear Medicine departments (Nancy Hospital, Bichat Hospital in Paris, Pasteur private hospital in Toulouse), with D.SPECT camera (Cyclopharma). The D.SPECT camera recording will be realized following the conventional camera recording and will not modify the routine programmed examination. Recording times of D.SPECT camera will be maximum 2 minutes for imaging with a strong activity of technetium-99m labeled dye and maximum 4 minutes for imaging with thallium-201 or with a low activity of technetium-99m labeled dye.6 study groups will be analyzed: 4 groups of patients initially doing stress tomoscintigraphy with thallium-201 (group 1) or with technetium-99m labeled dye and then testing 3 principal injection sequences (group 2, 3, 4), and 2 groups of patients initially doing "myocardial viability" assessment with rest tomoscintigraphy with thallium-201 (group 5) or technetium-99m labeled dye.
Recording comparison obtained with 2 cameras will be done according to qualitative and quantitative criteria on image quality and analyzing diagnosis concordance (presence, type and severity of observed abnormalities).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
with gamma-camera and D.SPECT camera
with gamma-camera and D.SPECT camera, in Toulouse centre
with gamma-camera and D.SPECT camera, in Nancy centre
with gamma-camera and D.SPECT camera, in Paris centre
rest thallium-201 tomoscintigraphy for myocardial viability assessment
rest technetium-99m tomoscintigraphy for myocardial viability assessment
Time frame: day 0
Time frame: day 0
Time frame: day 0
Time frame: day 0
Time frame: day 0
Time frame: day 0
Time frame: day 0
Central Hospital, Nancy, France
Other
Comparison Between Myocardial Tomoscintigraphies Using a Semiconductor Camera or a Conventional Camera According to Conditions of Examination Execution: Assessment of Infarction or Ischemia, Injected Dye and Sequence of Injections
Acronym: DSPECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00661323
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT00526474
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00617123
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT02690454
Cardiovascular Diseases, Heart Diseases
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
View Trial Details